Oxymorphone - Endo/Penwest

Drugs in R and D

Volumn 4, Issue 3, 2003, Pages 204-206

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EN 3202; MU OPIATE RECEPTOR AGONIST; OPIATE AGONIST; OXYCODONE; OXYMORPHONE; POLYSACCHARIDE; XANTHAN;

ANALGESIC ACTIVITY; ARTICLE; CANCER PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NAUSEA; OSTEOARTHRITIS; PRIORITY JOURNAL; SOMNOLENCE; TABLET FORMULATION; VERTIGO; VOMITING;

EID: 0037626715     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304030-00012     Document Type: Article

References (5)

1. Endo Pharmaceuticals Inc. FDA Accepts New Drug Application for Oxymorphone Extended Release And Immediate Release Formulations. Media Release: 19 Feb 2003. Available from URL: http://www.endo.com
2. Endo Pharmaceuticals Inc. Data from Studies Investigating Extended-Release Oxymorphone Presented Today at 10th World Congress on Pain. Media Release: 21 Aug 2002. Available from URL: http://www.endo.com
3. Endo Pharmaceuticals. Clinical Trial of New Opioid Product Shows Pain Reduction in Chronic Low Back Pain. Media Release: 20 Mar 2003. Available from URL: http://www.endo.com
4. Slatkin N, Frailey A, Ma T, et al. Oxymorphone extended-release offers long-term safety, effectiveness, and dose stability in cancer pain: results of a one-year interim report. Journal of Pain 4 (Suppl. 1):84, Mar 2003
5. Kivitz A, Ma C, Ahdieh H. Oxymorphone extended-release improves pain and quality of life in patients with osteoarthritis: results of a randomized, double-blind, placebo-controlled, dose-ranging study. Journal of Pain 4 (Suppl. 1): 80, Mar 2003